Close menu




FORMYCON AG

Photo credits: pixabay.com

Commented by André Will-Laudien on February 17th, 2021 | 10:39 CET

Cardiol Therapeutics, Formycon, Teva Pharmaceuticals: COVID in focus!

  • Biotechnology

According to recent statistics from the WHO, nowhere is research currently more intense than in the area of viral diseases. At least 248 vaccine projects have been initiated against COVID-19 since January 2020, but only the research projects have already been reported. But of course, we humans do not only fall ill from flu viruses and their dangerous mutants, but the permanent change in our lives alone intensifies diseases that arise from lack of exercise and contact and sometimes cause worse consequences than a flu-like effect. Everyone is currently looking to hopeful vaccine solutions, but several biotech and pharmaceutical companies can still make us healthier with new developments.

Read

Commented by Stefan Feulner on February 8th, 2021 | 07:10 CET

TUI, Pollux Properties, Formycon - When will the starting signal be given?

  • Investments

Currently, no question is heard more often: When will we see a return to normality? Light at the end of the tunnel is promised by the vaccines that are gradually being approved. The drugs against the Coronavirus, which are currently in various research phases, promise potential and could allow people to go about their daily lives as usual in the future. Through the action of these drugs, free, carefree travel could once again be possible. A boom seems pre-programmed.

Read

Commented by Stefan Feulner on December 21st, 2020 | 07:50 CET

CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!

  • Covid-19

The Corona pandemic continues to be the dominant topic of our time. Not a day goes by when new achievements in the fight against the pandemic come to public attention. The battle against Covid-19 is becoming a multi-billion-dollar business. In addition to the well-known profiteers, the vaccine manufacturers BioNTech and Pfizer, Moderna and AstraZeneca and many smaller companies are also profiting. Their potential is still largely unknown on the stock market and is far from being fully exploited.

Read

Commented by André Will-Laudien on December 10th, 2020 | 10:59 CET

AdTiger, Formycon, CureVac - Brilliant to the finish line!

  • Investments

It seems strange that a single company should be worth as much as all its colleagues in the industry put together. There is no such thing - there is! Yesterday, Tesla had a valuation of USD 625 billion at the start of the stock market - that's more than all other car manufacturers put together. Of course, Elon Musk's creature has not been a pure car manufacturer for a long time. Tesla is a high-tech Company, led by a visionary who brings a new great idea from his inner design studio to the light of day every few weeks. With his visions about essential facts of the human future, he is as creative as Karl Lagerfeld and as crazy as Jean-Paul Gaultier. But everyone is looking for the favor of their customers and genius is what we urgently need in a pandemic environment.

Read